All News
Let’s talk about SEX! >30% of pts wished their rheums asked them about sexual health, >50% pts with sexual dysfunction have RA. The presence of menopause, younger age, and children were assc with sexual dysfunction. presenter Dr D Flores Abstr#0145, #abst#0146 #ACR23 @RheumNow https://t.co/9AdoTtEwFp
TheDaoIndex KDAO2011 ( View Tweet)
Patient reported outcomes between clinic visits: worth doing?
RA pts starting ADA/UPA, n=150
ArthritisPower/PatientSpot app for PROs between visits
52% of CDAI change explained by PROs
Maybe a helpful tool in prioritising RA clinic reviews?
@RADoctor #ACR23 ABST0380 @RheumNow https://t.co/oTttAlIxQR
David Liew drdavidliew ( View Tweet)
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty
Dr. John Cush RheumNow ( View Tweet)
You should not tire of hearing this! Phase2 RCT of #dazodalibep -CD40L antagonist for #extra glandular & could also have #glandular problems in #Sjogrens was + improving Facit #fatigue & ESSPRI, etc. #GameChanger #ACR23 #ACRbest @ACRheum @RheumNow Pos#L10 https://t.co/DfChrAyslL
Janet Pope ( View Tweet)
PEXIVAS results: the reduced-dose GC regimen associated w/ ^ death, ESRD, and uncontrolled dz risk in severe GPA/MPA pts. Even greater risk in pts w/ creatinine levels > 300 μmol/L & in those tx w/ RTX induction. #ACR23 Plenary 0725 https://t.co/mBMrEaGj5k @rheumnow https://t.co/flAfYEKSXJ
Dr. Rachel Tate ( View Tweet)
DESIR cohort update in Abs #0513 shows axSpA pt imaging doesn't "worsen" after pregnancy. However, following 1st pregnancy, can see slight increase in L SIJ score, but typically not enough to define "worsening." #ACR23 https://t.co/HaYj3RQGFb @rheumnow https://t.co/5MQCXS1Kat
Dr. Rachel Tate ( View Tweet)
Acute pregnancy-related CV event risk found to be highest in pts w/ SLE+ APS, followed by primary APS, and SLE w/ LN. Most importantly, 25-30% of events happen post-partum! Monitor these pts carefully! #ACR23 Plenary 0722 #ACRbest https://t.co/yD5VFJ2SXh @rheumnow https://t.co/PDvzbs19fR
Dr. Rachel Tate ( View Tweet)
Prof Mustelin explains why Basic Science research is important in medicine. New ideas need:
👉discovery
👉explanation
👉 impact
#ACR23 @rheumnow #YearInReview #BasicScience https://t.co/t0W3GdUtWD
TheDaoIndex KDAO2011 ( View Tweet)
Who knew? VEXAS =cluster of findings from a somatic mutation N=110 studying retention of advanced Rx. #JAKi had far better retention than other #Rx. Although there could be channeling bias, I am impressed! Access for off label is a different issue #L03 #ACR23 @RheumNow @ACRheum https://t.co/RE4BVdZeWt
Janet Pope ( View Tweet)
Dr. Seo shares an interesting case report on the use of anti-TRBV9 Ab in a patient with AS.
Another potential treatment option for AS?🧐
Something to watch out for in the future.
#ACR23 @RheumNow @rheumarhyme https://t.co/y6mQ756TKK
sheila ( View Tweet)
A new way to die! #Ferroptosis may be a more important means of cell death. It’s an intracellular iron-dependent form of cell death that is distinct from apoptosis, necrosis, and autophagy #ACR23 @rheumnow #YearInReview https://t.co/DB7iuwuWTX https://t.co/v5Z2Od8mJ7
TheDaoIndex KDAO2011 ( View Tweet)
Q&A from RA-ILD Guidelines Presentation:
Q: "Why was AZA recommended but ABA was not?"
A: "The evidence was not as good for it so it was not included"
Can anyone explain this to me? Where is this amazing data for AZA in RA-ILD?
@RheumNow #ACR23
Mike Putman EBRheum ( View Tweet)
#ACR23 Year in Review. CAR-T cell showed promising results in #SLE based on case series but extrapolation to other RMD may be challenging.
-Myositis recurred after 7days, needing MMF
-No improvement in lung fibrosis #SSc
Longer-term data & trial data are needed @RheumNow https://t.co/4Zmjvr51Ab
Md Yuzaiful Md Yusof ( View Tweet)
More good data for benralizumab (IL5i) in EGPA, @TerrierBen
There may be additional benefit over MEPO given deeper eosinophil depletion
Checkout our recent editorial about this in @TheLancetRheum
@RheumNow #ACR23 https://t.co/1d2nITOuOs
Mike Putman EBRheum ( View Tweet)
Our work showed the PSAID-12 score done remotely correlated with in-person clinic assessment of tender (r=0.58) , swollen joint count (r= 0.51), pain (r=0.84). 21% of patients had low disease activity onPSAID12 assessment, Chan A #Abst0507 #ACR23 @RheumNow https://t.co/vorth2ko39 https://t.co/Q2Y3ApD47E
Dr. Antoni Chan ( View Tweet)
Why do we do translational research?
Dr Mustelin outlines different goals of basic science in #yearinreview
I would emphasize the #1: understanding pathogenesis is key to address clinical challenges
Overall “we have much more work to do than we care to admit”
@RheumNow #ACR23 https://t.co/QtBO3Go3gD
Aurelie Najm ( View Tweet)
Year in review: Long-term outcome of pts in the MAINRITSAN trials
Better outcome in pts who received RTX every 6 months for 18 months.
Implications? May consider shorter duration of maintenance tx (<36mos)?
#ACR23 @RheumNow #vasculitis https://t.co/18cXBlfxSG
sheila ( View Tweet)
Great Dr. Seo presents a great quote from Prof Seza Ozen during #ACR23 YiR "What you think of as a rare manifestation of a common disease is probably a common presentation of a disease you are not aware of (yet.)" A call to arms to continue to be curious! @RheumNow https://t.co/zVcIpHZznt
Dr. Rachel Tate ( View Tweet)
RTX-induction subgroup, ADVOCATE
Encouraging results (remission 71% vs 56% plbo wk 52), but never forget RTX was NOT redosed at month 6, so pts randomized to prednisone had NO TREATMENT from wk 20 - wk 52
Take results w/grain of salt
@RheumNow #ACR23 #ACRBest @anisha_dua https://t.co/zVhRX3IbiL
Mike Putman EBRheum ( View Tweet)
Regarding monitoring of ILD: "TLC takes a lot of time and is not necessary for follow up PFTs" @sclerodermaUM
Very nice pearl; I have been including TLC in subsequent PFTs, probably not necessary
Will change my practice immediately & save patients time
@RheumNow #ACR23
Mike Putman EBRheum ( View Tweet)